NW BIO Completes Asset Acquisition/Disposition

TL;DR

NW BIO filed an 8-K on 4/7/26 for an asset deal that closed 10/24/25.

AI Summary

On April 7, 2026, NORTHWEST BIOTHERAPEUTICS INC filed an 8-K report detailing the completion of an acquisition or disposition of assets. The period of report for this transaction was October 24, 2025.

Why It Matters

This filing indicates a significant corporate action, potentially altering the company's asset base and future strategic direction.

Risk Assessment

Risk Level: medium — Asset acquisitions or dispositions can significantly impact a company's financial health and operational focus, introducing uncertainty.

Key Players & Entities

• NORTHWEST BIOTHERAPEUTICS INC (company) — Filer of the 8-K report
• 0001072379 (company) — CIK number for NORTHWEST BIOTHERAPEUTICS INC
• 2026-04-07 (date) — Filing date of the 8-K report
• 2025-10-24 (date) — Period of report for the asset transaction

FAQ

Key Financial Figures

• $0.001 — registered: Common Stock, par value, $0.001 per share NWBO OTCQB Indicate by
• $1.9 million — ts of a purchase price of approximately $1.9 million (1.4 million) and payment of the then o
• $8.3 million — the acquisition, totaling approximately $8.3 million. Certain excluded amounts (relating to
• $0.7 million — d by the Seller, totaling approximately $0.7 million. The unpaid balance of installment paym

Filing Documents

• tm2611284d1_8k.htm (8-K) — 24KB
• 0001104659-26-040260.txt ( ) — 183KB
• nwbo-20251024.xsd (EX-101.SCH) — 3KB
• nwbo-20251024_lab.xml (EX-101.LAB) — 33KB
• nwbo-20251024_pre.xml (EX-101.PRE) — 22KB
• tm2611284d1_8k_htm.xml (XML) — 3KB

01. Completion of Acquisition or Disposition of Assets

Item 2.01. Completion of Acquisition or Disposition of Assets. As previously announced, on October 24, 2025 (the "Closing Date"), Northwest Biotherapeutics, Inc. (the "Company") completed the acquisition of Advent BioServices Ltd. ("Advent"), a United Kingdom-based contract development and manufacturing organization (CDMO), from Toucan Holdings LLC (the "Seller"), pursuant to an acquisition agreement dated as of August 27, 2025. Prior to the acquisition, Advent provided the Company with product development, manufacturing, cryostorage and distribution services for the Company's DCVax product platform pursuant to various service agreements. Following the acquisition, Advent became a wholly owned subsidiary of the Company. The consideration for the acquisition is payable in installments over two years, beginning 3 months after the Closing Date, with potential acceleration after regulatory approval of the Company's DCVax-L product. The consideration for the acquisition consists of a purchase price of approximately $1.9 million (1.4 million) and payment of the then outstanding net amount of accounts payable owed by the Company to Advent for manufacturing and related services already provided under services contracts prior to the acquisition, totaling approximately $8.3 million. Certain excluded amounts (relating to accounts payable for non-Company matters prior to the acquisition date) were retained by the Seller, totaling approximately $0.7 million. The unpaid balance of installment payments will accrue interest at 7.5% annually. At closing, the Company received back 12 million shares of the Company's common stock and 5.5 million Company stock options, which were previously issued to Advent as compensation for services. The returned shares were retired to the Company's treasury and the options were cancelled. The acquisition constitutes a related party transaction, because the Company's Chairperson, Chief Executive Officer, and President, Linda Powers, is the cont